Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-23, Stock:PFE, The news for the past five days is as follows:
2019-05-16: NEWS1: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS2: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS3: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS4: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS5: Pfizer Gains After Being Named 'Top Pick' by Credit Suisse.NEWS6: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS7: Here are the biggest analyst calls of the day: Macy&apos;s, Pfizer, Owens Corning & more.NEWS8: Stocks making the biggest moves premarket: Walmart, Pfizer, PG&E, Sony, Tesla & more.NEWS9: Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?.
2019-05-17: NEWS1: After Hours Most Active for May 17, 2019 :  QCOM, VIPS, QQQ, VEON, PFE, WFC, ATI, INTC, WMT, CECO, TEF, IQ.NEWS2: After Hours Most Active for May 17, 2019 :  QCOM, VIPS, QQQ, VEON, PFE, WFC, ATI, INTC, WMT, CECO, TEF, IQ.NEWS3: Health Care Sector Update for 05/17/2019: ACHN, OTLK, MOR, JNJ, PFE, ABT, MRK, AMGN.NEWS4: Health Care Sector Update for 05/17/2019: ACHN, OTLK, MOR, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs.NEWS6: Dow 30 Stock Roundup: Walmart, Cisco Earnings Impress.
2019-05-20: NEWS1: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS2: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS3: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS4: Health Care Sector Update for 05/20/2019: MDCO, QGEN, INNT, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Health Care Sector Update for 05/20/2019: MDCO, QGEN, INNT, JNJ, PFE, ABT, MRK, AMGN.
2019-05-21: NEWS1: Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint.NEWS2: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.NEWS3: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.NEWS4: Better Buy: AbbVie vs. Pfizer.NEWS5: Better Buy: AbbVie vs. Pfizer.NEWS6: Better Buy: AbbVie vs. Pfizer.NEWS7: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.
2019-05-22: NEWS1: Health Care Sector Update for 05/22/2019: OBLN, CODX, AFMD, JNJ, PFE, ABT, MRK, AMGN.NEWS2: Health Care Sector Update for 05/22/2019: OBLN, CODX, AFMD, JNJ, PFE, ABT, MRK, AMGN.NEWS3: Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint.NEWS4: Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint.

Answer: Decrease